News

Conference Coverage

Trifluridine/Tipiracil Plus Bevacizumab Associated with Longer Lasting Quality of Life Among Patients with Refractory Metastatic Colorectal Cancer

06/30/2023

Allison Casey ;

In the SUNLIGHT trial, patients with colorectal cancer who were in the trifluridine/tipiracil plus bevacizumab arm had a longer time to deterioration of health-related quality of life compared with patients in the trifluridine/tipiracil alone...

In the SUNLIGHT trial, patients...

06/30/2023

Oncology

Conference Coverage

Characterizing the Somatic and Germline Mutational Landscape of Colorectal Cancer

06/30/2023

Allison Casey ;

The most common somatic driver mutations and pathogenic germline variants among patients with colorectal cancer were identified in this analysis.

The most common somatic driver...

06/30/2023

Oncology

Carlotta Antoniotti, MD, PhD, University of Pisa

Videos

Atezolizumab With FOLFOXIRI Plus Bevacizumab for Metastatic Colorectal Cancer in the First-Line Setting

06/22/2023

Carlotta Antoniotti , MD, PhD;

At the 2023 ASCO annual meeting, Carlotta Antoniotti, MD, PhD, shares data from the AtezoTRIBE study evaluating the addition of atezolizumab to FOLFOXIRI plus bevacizumab for metastatic colorectal cancer.

At the 2023 ASCO annual meeting,...

06/22/2023

Oncology

Lars Henrik Jensen, MD, University Hospital of Southern Denmark

Videos

Neoadjuvant Chemotherapy for Locally Advanced Colorectal Cancer

06/14/2023

On site at ASCO 2023, Dr Lars Henrik Jensen shares results from the phase 3 NeoCol trial evaluating the addition of neoadjuvant chemotherapy to initial surgery for patients with locally advanced colon cancer.

On site at ASCO 2023, Dr Lars...

06/14/2023

Oncology

Cathy Eng, MD, Vanderbilt-Ingram Cancer Center

Videos

Clinical Trials in Treatments for Anal Cancer

04/20/2023

At the 2023 Great Debates and Updates in Gastrointestinal Malignancies meeting, Cathy Eng, MD, offered her perspectives on the current and upcoming clinical trials for treatments of anal cancer.

At the 2023 Great Debates and...

04/20/2023

Oncology

Anjee Davis, MPPA, Fight Colorectal Cancer

Videos

The Importance of Patient Advocacy

04/01/2023

At the 2023 Great Debates & Updates in Gastrointestinal Malignancies in Chicago, President of Fight Colorectal Cancer, Anjee Davis, MPPA, shares the importance of patient advocacy and how clinicians can help support and empower their patients...

At the 2023 Great Debates &...

04/01/2023

Oncology

Alison Schram, MD, Memorial Sloan Kettering Cancer Center

Videos

Targeting Class II/III Alterations in BRAF Inhibitors

03/16/2023

At 2023 ESMO Targeted Anticancer Therapies Congress, Alison Schram, MD, discusses the class II/III alterations of BRAF inhibitors.

At 2023 ESMO Targeted Anticancer...

03/16/2023

Oncology

News

Neoadjuvant Chemotherapy as a Treatment Option for Operable Colon Cancer

02/10/2023

Allison Casey ;

Preoperative oxaliplatin-fluoropyrimidine chemotherapy is safe and may improve 2-year disease control and other outcomes for patients with operable colon cancer, according to mature results from a phase 3 trial.

Preoperative...

02/10/2023

Oncology

Sebastian Stintzing, MD, Charité — Berlin University of Medicine

Videos

Initial Cycle of Chemotherapy Does Not Influence Efficacy of First-Line FOLFIRI Plus Cetuximab for RAS Wild-Type Colorectal Cancer

02/08/2023

Sebastian Stintzing, MD, shares results from the phase 3 FIRE-4 trial showing the administration of an initial cycle of chemotherapy had no effect on the efficacy of first-line FOLFIRI plus cetuximab therapy for patients with RAS wild-type...

Sebastian Stintzing, MD, shares...

02/08/2023

Oncology

Stacey Cohen, MD, Fred Hutchinson Cancer Center

Videos

What is the Optimal Timing to Test for Circulating Tumor DNA to Detect MRD in Colorectal Cancer?

02/02/2023

Stacey Cohen, MD, reviews results from a study evaluating the optimal timing to test for circulating tumor DNA to detect MRD following surgery in patients with colorectal cancer.

Stacey Cohen, MD, reviews...

02/02/2023

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology